Persistently Low ALP Can Be the First Clue to Hypophosphatasia
A routine metabolic panel can hide a rare inherited bone disorder in plain sight. Persistently low alkaline phosphatase should immediately raise suspicion for hypophosphatasia (HPP), especially when the clinical picture includes stress fractures, atypical fractures, premature tooth loss, chronic musculoskeletal pain, or unexplained calcifications. HPP arises from loss-of-function variants in ALPL, the gene encoding tissue nonspecific alkaline phosphatase, and the downstream effect is a failure of normal mineralization in bone and teeth. In practical terms, pyrophosphate accumulates, hydroxyapatite formation is impaired, and skeletal tissue cannot mineralize normally. The same enzymatic defect can also drive ectopic calcium deposition in the kidneys or periarticular soft tissues.
A low ALP result does not belong on a diagnostic shrug list.
The disorder matters because the laboratory abnormality is common in routine testing, but the disease behind it is not. Adult clinicians often see the number before they see the syndrome, and that sequencing delays recognition. The biological consequences extend beyond the skeleton. Tissue nonspecific alkaline phosphatase is also needed for activation of vitamin B6 in the brain, which helps explain why some children with HPP develop vitamin B6-responsive seizures. Inheritance can be autosomal dominant or recessive, yet phenotype does not map cleanly onto genotype, so family history alone cannot exclude the diagnosis.
Bone, Teeth, Kidneys, and Brain Can All Be Involved
HPP spans a wide clinical spectrum, from severe perinatal disease to mild adult-onset presentations. The condition is commonly divided into five forms based on age at first symptom onset: perinatal, infantile, childhood, adult, and odonto, the dental-only form. That classification is useful, but bedside care rarely stays inside neat categories. Adults may present with muscle pain, bone pain, joint pain, weakness, fatigue, headache, sleep disturbance, hypercalciuria, nephrocalcinosis, abnormal dentition, or premature loss of primary teeth. Low bone turnover is a central feature, and fracture risk is increased, particularly for stress fractures and atypical fractures.
Misdiagnosis remains a major barrier to care. Patients are often labeled with fibromyalgia, chronic fatigue syndrome, or osteoarthritis before HPP is ever considered. The overlap is understandable, since pain and fatigue are nonspecific, but the fix is straightforward: review the biochemistry and ask the dental history. Early loss of primary teeth with intact roots is a particularly useful clue in children. In adults, chondrocalcinosis and recurrent stress injury should push HPP higher on the differential, especially when ALP remains below the expected range on repeated testing.
Age and sex matter when interpreting the lab value. Children and adolescents normally have much higher ALP levels than adults because of growth, and reference ranges differ by sex, particularly during periods of puberty. A single low value in the wrong age band can mislead clinicians in either direction. Confirmation is strengthened by measuring pyridoxal 5′ phosphate (PLP), the active vitamin B6 metabolite that tends to accumulate in HPP, and urinary phosphoethanolamine (PEA), which can also be elevated.
Diagnosis Demands More Than a Single Lab Number
Low ALP alone does not equal HPP. Several other states and medications can suppress bone turnover and drive ALP downward, including antiresorptive therapy, tamoxifen, hypoparathyroidism, hypothyroidism, Cushing syndrome, and zinc deficiency. This is where careful interpretation becomes essential, because the wrong assumption can lead to the wrong treatment. A patient with low bone density may be sent toward bisphosphonate therapy before HPP is excluded, and in the setting of HPP that can be harmful. Antiresorptive therapy can further suppress already low bone turnover and may increase the risk of atypical femur fracture.
The diagnostic approach should therefore ask three questions at once: is ALP persistently low, are there compatible clinical features, and are supportive biomarkers or genetic data available? More than 480 pathogenic or likely pathogenic ALPL variants have been cataloged, and carrier frequency for pathogenic or likely pathogenic variants has been reported at approximately one in 341, or 0.3%, in large genomic screening of unselected populations. Even with that breadth of genetic data, genotype-phenotype correlation remains limited. Genetic counseling can still be valuable because inheritance patterns and disease severity vary widely, including within the same family.
Treatment Choices Depend on Disease Burden
Management of HPP is multidisciplinary by necessity. Endocrinology, genetics, dentistry, nephrology, neurology, and orthopedics may all have a role depending on the organ systems involved. The therapeutic conversation also has to be individualized, because not every patient with mild adult-onset disease needs enzyme replacement. The burden of therapy, medication side effects, and the logistics of long-term injections all matter.
Asfotase alfa remains the only approved pharmacologic treatment for perinatal, infantile, and juvenile hypophosphatasia. It is a bone-targeted recombinant TNSALP that improves skeletal mineralization and has been associated with better pulmonary function, reduced hypercalcemia, and improved muscle strength, with the most pronounced benefit in severely affected patients. The treatment, however, is not simple. It requires frequent subcutaneous injections, typically three to six times per week, and adult long-term data remain limited. For patients with milder disease, the decision to treat should balance symptom burden, fracture history, renal findings, and overall functional impact against the realities of chronic therapy.
Monitoring is equally specific. Serum ALP rises substantially during treatment, often into the thousands, so it cannot be used to titrate dose or judge response. Follow-up should instead track serum PLP, calcium, phosphorus, parathyroid hormone, renal function, and urinary calcium, with periodic renal and ophthalmic imaging to screen for calcifications. High-dose calcium and vitamin D supplementation should be avoided unless there is a compelling reason, because excessive replacement can increase the risk of nephrocalcinosis and nephrolithiasis. In a disorder already prone to ectopic calcification, indiscriminate supplementation can create new problems.
Why Early Recognition Changes the Bedside Conversation
Earlier recognition of HPP changes more than the diagnosis itself. It can prevent exposure to therapies that worsen low-turnover bone disease, redirect care toward appropriate genetic counseling, and focus evaluation on fractures, dental loss, renal calcification, and neurologic symptoms that might otherwise be dismissed as unrelated. It also gives clinicians a framework for explaining why a patient with pain, fatigue, or recurrent fractures does not fit the usual bone disease script.
The practical message for endocrine, bone, and primary care clinics is direct: low ALP is not a benign curiosity when it is persistent. It is a clue to a disorder that reaches into the skeleton, teeth, kidneys, and nervous system, and the cost of missing it can be substantial. As awareness grows and testing becomes more familiar, the next missed diagnosis should be fewer than the last.